FDA Clears PRF Technologies' OcuRing™-K for Phase II Trial in Post-Cataract Pain, Advancing Key Drug Candidate
PRFX is trading near its 52-week low of $1.797 (15% above the low).
Summary
PRF Technologies announced that the FDA has cleared its Investigational New Drug (IND) application for OcuRing™-K, enabling the initiation of a Phase II clinical trial. OcuRing™-K is a novel, drop-less, sustained-release ocular drug-delivery platform designed to address post-cataract pain and inflammation. This regulatory clearance is a significant milestone for the clinical-stage company, de-risking the asset and advancing a key product candidate into the next stage of clinical development. For a company of this size, progressing to Phase II is a crucial step towards potential market entry in the large cataract surgery market. Investors will now monitor the planned initiation of the multi-center Phase II trial in the second half of 2026 and subsequent data readouts.
At the time of this announcement, PRFX was trading at $2.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $1.80 to $17.95. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.